Table S1. Characteristics of PrEP Tweets by FDA Approval of Descovy (N = 786)

Variable	Before FDA Approval N (%)	After FDA Approval N (%)	p-value
TPB Construct			
Attitude	26 (6.5%)	27 (7.0%)	.797
Perceived Norm	8 (2.0%)	3 (.7%)	.142
Perceived behavioral control	5 (1.3%)	8 (2.1%)	.371
Intention/Behavior	25 (6.3%)	37 (9.6%)	.087
Information/ Knowledge	82 (20.6%)	107 (27.6%)	.020
Actual barriers	176 (44.1%)	122 (31.5%)	<.001
Other	77 (19.3%)	83 (21.4%)	.454
Source			
Individual	323 (81.0%)	302 (78.0%)	.311
Organization	76 (19.0%)	85 (22.0%)	

Notes: P-values were calculated from χ^2 tests; all cells had expected values over 5.

Table S2. Types of Actual Barriers by FDA Approval of Descovy (N = 298)

Variable	Before FDA Approval N (%)	After FDA Approval N (%)	p-value
Cost	68 (38.6%)	50 (41.0%)	.684
Access	69 (39.2%)	37 (30.3%)	.115
Issues with Pharmaceutical Company	33 (18.8%)	27 (22.1%)	.474
Stigma	6 (3.4%)	8 (6.6%)	.207

Notes: P-values were calculated from χ^2 tests; all cells had expected values over 5.